Drugs that contain Fingolimod Hydrochloride
1. Gilenya patents expiration
GILENYA's oppositions filed in EPO
GILENYA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(5 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(6 years ago) | |
|
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(4 years ago) | |
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(1 year, 11 months from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(2 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(3 years from now) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(3 years from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(3 years from now) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(7 years from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 11, 2021 |
| New Patient Population(NPP) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of autoimmune disease; Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating...
Dosage: CAPSULE;ORAL
How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage
GILENYA family patents
